Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Public Health

Background:

• Decades of research confirm the link between low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD) risk.
• Despite established guidelines, LDL-C goal attainment rates are significantly low in both primary and secondary prevention.
• Suboptimal initiation, intensification, and adherence to lipid-lowering therapies contribute to this gap.

Purpose of the Study:

• To highlight the low rates of LDL-C goal attainment.
• To identify clinician-related factors and systemic barriers hindering effective dyslipidemia management.
• To emphasize the public health imperative of increasing LDL-C goal attainment for cardiovascular risk reduction.

Main Methods:

• Review of current literature and clinical guidelines on LDL-C management.
• Analysis of factors contributing to suboptimal lipid-lowering therapy.
• Discussion of strategies to improve patient outcomes and adherence.

Main Results:

• Low rates of LDL-C goal attainment persist across patient populations.
• Clinical inertia, inconsistent risk assessment, and access barriers impede effective treatment.
• LDL-C reduction is directly associated with decreased cardiovascular event risk.

Conclusions:

• Rethinking dyslipidemia management is essential, requiring a multi-stakeholder approach.
• Implementing LDL-C measurement as a health system metric and encouraging upfront combination therapy are key strategies.
• Leveraging pharmacists, telehealth, and EMRs can enhance treatment efficacy and adherence.